StemCell Therapy

he globalstem cell and regenerative medicines marketshould grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

More Info of Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11723

Read more:
Stem Cell And Regenerative Therapy Market : Segmentation, Industry Trends and Development size COVID-19 2024 - 3rd Watch News

Wearing masks and other personal protective equipment (PPE) can slow the spread of COVID-19. The U.S. Centers for Disease Control and Prevention recommends everyone wear some kind of face covering in public places, especially where social distancing is difficult to maintain. And health workers are donning additional coverings, such as gowns. Yet all such protective gear shares one significant problem: people still risk becoming infected with the novel coronavirus if they accidentally touch areas of the fabric that are contaminated with viral particles. So researchers are working to develop cloth that could inactivate or repel coronavirusesideally including the one that causes COVID-19and other pathogens.

People can transfer infectious particles to their hands if they touch the front of a mask during use or when they remove gowns or other PPE, according to Chandan Sen, director of the Indiana Center for Regenerative Medicine and Engineering at Indiana University. He and his colleagues have been developing a way to render those particles and other infectious agents harmless. The team researches electroceutical materials that wirelessly generate electric fields across the surface of the fabric, Sen says. Those fields can disrupt the behavior of bacteria or viruses on the cloth.

The beauty of this [technology] is the inherently simple design, he says. The polyester material is printed with alternating spots of silver and zinc resembling polka dots. They are one to two millimeters wide and spaced one millimeter apart. When the electroceutical material is dry, it functions as an ordinary fabric. But if it gets dampenedsay, with saliva, vapor from a coughed up droplet or other bodily fluidsions in the liquid trigger an electrochemical reaction. The silver and zinc then generate a weak electric field that zaps pathogens on the surface.

The researchers co-developed the material with the biotechnology company Vomaris Innovations in 2012. Last year they showed that the technology could be used to treat bacterial biofilms in wounds. A clinical trial is underway to further evaluate the fabrics effectiveness as a Food and Drug Administrationcleared dressing for wound care, Sen says.

In response to the COVID-19 pandemic, Sens team tested its existing material on a different coronavirus strain that causes a respiratory illness in pigs and on an unrelated type of pathogen called a lentivirus. We wanted to know how broadly this principle could be applicable, he says. In a study posted on the preprint server ChemRxiv in May, Sens team reported that its electroceutical fabric destabilized both viruses, leaving them unable to infect cells. The researchers plan to submit the results to a peer-reviewed journal as well.

To study the fabrics action, they placed a liquid solution containing viral particles onto the electroceutical fabric and a polyester control fabric without the metal dots. After the droplets were fully absorbed, and the samples had rested for one to five minutes, the researchers recovered viral particles from both fabrics and tested whether they could still infect the types of cells they typically target.

The data presented here show that, of the total virus that was recovered, a significant percentage was inactivated, says Jeff Karp, a professor of medicine at Brigham and Womens Hospital in Boston and co-leader of an N95 respirator working group at the Massachusetts General Brigham Center for COVID Innovation. Karp, who was not involved with the study, adds that the researchers did not test all of the virus that they had placed on the cloth. In fact, the majority of virus was not recovered from the textiles examined in this study, he says. Sen responds that his team focused on sampling only enough viral particles to show that the fabric had rendered them unable to infect cells. The researchers recovered roughly 44 percent of the particles from the electroceutical fabric samples that had rested for one minute. And they retrieved 24 percent of them from the samples that had rested for five minutes.

The materials virus-fighting abilities have not been tested specifically on SARS-CoV-2, the coronavirus that causes COVID-19. The researchers findings with the two viruses they studied, however, gave them hope that this could apply more widely, Sen says. He adds that large-scale manufacturing of the electroceutical fabric is already possible and that the costs of producing it are relatively low. The metal dots could be printed directly onto the front surfaces of masks, he suggests. Or an electroceutical fabric could be inserted between the front of a mask and the wearers face.

If a virus-stopping PPE material were widely available, it could limit the novel coronaviruss ability to spread. There is a huge unmet need to better understand modes of viral transfer that lead to virus transmission, Karp says. As we develop a better understanding of this, there is a huge immediate need to develop and quickly apply solutions that can reduce transmission.

Metal dots are not the only potential approach. Paul Leu, director of an advanced materials laboratory at the University of Pittsburgh, and his colleagues are developing a textile coating that repels bodily fluids, proteins and bacteria. It also repels one strain of adenovirus that causes respiratory illness and another that causes conjunctivitis, as reported in ACS Applied Materials & Interfaces in April. Leus team has also not tested the material with the novel coronavirus itself, however. The main thing with testing [the coating on] SARS-CoV-2 is the biosafety level you need to test it, because its very hazardous, he says. Still, his team plans to see how well textiles with this coating repel a different coronavirus.

Leu says the coating, which remains repellent even after ultrasonic washing and scraping with a razor blade, could make PPE safer for wearers to take off. It could also be used on hospital bed linens, drapes and waiting room chairs, the researchers note in the study. But Leu points out that the coating is intended for use with medical textiles that are already considered reusable. His team has not tested it on single-use masks or N95s, but he thinks it could potentially damage them. Still, he says, the coating could work well for cloth masks such as those now being worn by many among the general public.

By developing materials that kill or repel viruses, researchers hope to make masks and other protective gear safer to remove and more effective against all viruses. If the common person were to have PPE that wouldnt spread infection, Sen says, I think thats a big, big deal.

Read more about the coronavirus outbreakfromScientific Americanhere. And read coverage from ourinternational network of magazines here.

Read the original here:
Electrified Fabric Could Zap the Coronavirus on Masks and Clothing - Scientific American

CHICAGO, June 23, 2020 /PRNewswire/ -- According to the new market research report "Biopreservation Market by Type (Media (Sera), Equipment (Thawing Equipment, Alarms, Freezers)), Biospecimen (Human Tissue, Stem Cells, Organs), Application (Therapeutic, Research, Clinical Trials), End User (Hospitals, Biobank) - Global Forecast to 2025", published by MarketsandMarkets, the Biopreservation Market is projected to reach USD 4.9 billion by 2025 from USD 3.1 billion in 2020, at a CAGR of 9.1% between 2020 and 2025.

MarketsandMarkets Logo

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=842

Increasing R&D investments, advances in biobanking and the growing trend of conserving cord blood stem cells of newborns, rising investments in regenerative medicine research, and the increasing demand for personalized medicine are the major factors driving the growth of the biopreservation media and equipment market.

The biopreservation media segment accounted for the largest share of the biopreservation media and equipment market.

Based on type, the biopreservation media and equipment market is segmented into biopreservation media and equipment. The biopreservation media segment accounted for the largest share of the global biopreservation media and equipment market in 2019. The large share of this segment is attributed to the increasing research activities in stem cell therapy, regenerative medicine, and personalized medicine.

Browsein-depth TOC on"Biopreservation Market"

286 Tables 35 Figures233 Pages

The human tissue samples segment accounted for the largest share of the biopreservation media and equipment market in 2019.

On the basis of biospecimen, the biopreservation media and equipment market is segmented into human tissue samples, organs, stem cells and other biospecimens. The human tissue samples segment accounted for the largest share of the global biopreservation media and equipment market in 2019. The large share of this segment is attributed to the increasing number of biobanks and growth in R&D spending for life science research.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=842

North America to dominate the biopreservation media and equipment market during the forecast period

In 2019, North America dominated the biopreservation media and equipment market, followed by Europe. The major factors driving the growth of this market include increasing research activities in the field of regenerative medicine, rising R&D investment in life sciences research and growing awareness of personalized medicine.

The prominent players in this market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Avantor, Inc. (US) ThermoGenesis Holdings, Inc. (US), Bio-Techne Corporation (US), BioLife Solutions, Inc. (US), Exact Sciences Corporation (US), (US), Worthington Industries, Inc. (US), and Chart Industries, Inc. (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=842

Browse Related Reports:

Biobanking Marketby Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) - Global Forecast to 2022

Story continues

https://www.marketsandmarkets.com/Market-Reports/biobanking-devices-market-594.html

Lab Automation Marketby Equipment and Software (Robotic Arms, Microplate Readers, LIMS), Applications (Drug Discovery, Clinical Diagnostics, Genomics), End Users (Biotechnology and Pharmaceuticals, Diagnostic Labs) - Global Forecast to 2022

https://www.marketsandmarkets.com/Market-Reports/lab-automation-market-1158.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish MehraMarketsandMarkets INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biopreservation-media-storage-equipment-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/biopreservation.asp

View original content:http://www.prnewswire.com/news-releases/biopreservation-market-worth-4-9-billion-by-2025--exclusive-report-by-marketsandmarkets-301081801.html

SOURCE MarketsandMarkets

View original post here:
Biopreservation Market Worth $4.9 Billion by 2025 - Exclusive Report by MarketsandMarkets - Yahoo Finance

The study on the Cord Blood Banking Marketby Brand Essence Market Research is a compilation of systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also offers a precise analysis of the key challenges and growth prospects awaiting key players of the Cord Blood Banking market, including a concise summary of their corporate strategies and competitive setting.

In 2018, the Global Cord Blood Banking Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=12680&RequestType=Sample

Cord Blood Banking Market is valued at USD 1.24 Billion in 2018 and expected to reach USD 2.83 Billion by 2025 with the CAGR of 12.5 % over the forecast period.

A cord blood bank is a facility that stores umbilical cord blood for future use. Both private and public cord blood banks are developed in response to the reliable for cord blood in treating diseases of the blood and immune systems. Private or family cord blood banks are developed for autologous use or directed donation for a family member. Physicians recommend blood bank facility for a variety of reasons. Nowadays, Umbilical cord blood is used to treat many life-threatening diseases including leukemia, certain other cancers, and blood, immune and metabolic disorders. Over 30,000 transplants worldwide have been performed using stem cells from umbilical cord blood and because stem cell technologies continue to advance, the opportunities to utilize preserved cord blood and are steadily increasing. For example, Cryo-Cells umbilical cord blood banking service processes and cryogenically preserves these cells for potential therapeutic use.

Global cord blood banking market report is segmented on the basis of bank type, and regional & country level. Based upon bank type, cord blood banking market is classified as private, public, and hybrid. The regions covered in this Global Cord blood banking market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Cord blood banking market is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Cord blood banking Market Report

Global Cord Blood Banking Market Report covers prominent players are like Singapore Cord Blood Bank, CBR Systems, ViaCord LLC, Cordlife, FamiCord, Cryo-Save, Americord, Global Cord Blood Corporation, LifeCell and Jeevan Stem Cell Foundation and others.

Increasing Demand for Umbilical Cord Blood (UCB) Units for Regenerative Medicine Purposes is one of the Major Factors Drive the Market growth.

Increasing demand for umbilical cord blood (UCB) units for regenerative medicine purposes is expected to drive the growth of cord blood banking market. An increase in the number of UCB transplants specifies an expansion of utility in a broad spectrum of disease conditions. For example, the loaded umbilical cord blood in the stem cell can treat cancer, blood diseases like anemia, and some immune system disorders, which disrupt bodys ability to defend it. Apart from that, additional potential applications of UCB include hematopoietic transplantation, immunotherapy, and tissue engineering and regenerative medicine. In addition, increasing prevalence and incidence rate of chronic diseases is also supplementing the market growth. For example, According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. The increasing number of cancer patients is a major driver for the growth of stem cell/cord blood banking market. In 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States. However, stringent regulatory requirements may hamper the market growth. In spite of that, increasing technological developments in the field of cord blood storage and processing are also expected to provide an opportunity for the further growth of the market.

North America is Expected to Dominating the Global Cord Blood Banking Market.

North America market is anticipated to grow at a significant rate in the global cord blood banking market in upcoming years, mainly due to the growing demand for the umbilical cord blood in stem cell analysis in this region. In addition, well developed healthcare infrastructure and high adoption of advanced technology in healthcare in this region are also supplementing the market growth. The umbilical cord blood banking may be public and private. In North America, An estimated 4.0 million umbilical cord blood units have been saved for private or family use. In 2017, there are 28 public cord blood banks in North America. These banks have sufficient capacity for those demanding a donation of cord blood. The European cord blood banking market is a second largest market followed by Asia pacific.

By Bank Type:

By Regional & Country Analysis:

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Cord Blood Banking Market Size Growth Rate by Type (2014-2025)1.4.2 Topical Products1.4.3 Botulinum1.4.4 Dermal Fillers1.4.5 Chemical Peels1.4.6 Microabrasion Equipment1.4.7 Laser Surfacing Treatments1.5 Market by Application1.5.1 Global Cord Blood Banking Market Share by Application (2014-2025)1.5.2 Hospitals1.5.3 Dermatology Clinics1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Cord Blood Banking Market Size2.2 Cord Blood Banking Growth Trends by Regions2.2.1 Cord Blood Banking Market Size by Regions (2014-2025)2.2.2 Cord Blood Banking Market Share by Regions (2014-2019)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities

3 Market Share by Key Players3.1 Cord Blood Banking Market Size by Manufacturers3.1.1 Global Cord Blood Banking Revenue by Manufacturers (2014-2019)3.1.2 Global Cord Blood Banking Revenue Market Share by Manufacturers (2014-2019)3.1.3 Global Cord Blood Banking Market Concentration Ratio (CR5 and HHI)3.2 Cord Blood Banking Key Players Head office and Area Served3.3 Key Players Cord Blood Banking Product/Solution/Service3.4 Date of Enter into Cord Blood Banking Market3.5 Mergers & Acquisitions, Expansion Plans

Read More: https://industrystatsreport.com/Lifesciences-and-Healthcare/Cord-Blood-Banking-Market-Size-and-share/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Top Trending Reports:

https://brandessenceresearch.com/pharmaceutical/marine-pharmaceutical-market-industry

https://brandessenceresearch.com/agriculture/industrial-hemp-market-size

https://brandessenceresearch.com/healthcare/hematology-analyzer-and-reagent-market

https://brandessenceresearch.com/healthcare/esoteric-market-by-test

Read the original here:
Global Cord Blood Banking Market 2020 Production, Revenue, Average Product Price and Market Shares of Key Players 2025 - Jewish Life News

Wearing masks and other personal protective equipment (PPE) can slow the spread of Covid-19. The USCenters for Disease Control and Prevention recommends everyone wear some kind of face-covering in public places, especially where social distancing is difficult to maintain. And health workers are donning additional coverings, such as gowns. Yet all such protective gear shares one significant problem: people still risk becoming infected with the novel coronavirus if they accidentally touch areas of the fabric that are contaminated with viral particles. So researchers are working to develop cloth that could inactivate or repel coronavirusesideally including the one that causes Covid-19and other pathogens.

For latest updates and live news on coronavirus, click here

People can transfer infectious particles to their hands if they touch the front of a mask during use or when they remove gowns or other PPE, according to Chandan Sen, director of the Indiana Center for Regenerative Medicine and Engineering at Indiana University. He and his colleagues have been developing a way to render those particles and other infectious agents harmless. The team researches electroceutical materials that wirelessly generate electric fields across the surface of the fabric, Sen says. Those fields can disrupt the behaviour of bacteria or viruses on the cloth.

The beauty of this [technology] is the inherently simple design, he says. The polyester material is printed with alternating spots of silver and zinc resembling polka dots. They are one to two millimetres wide and spaced one millimetre apart. When the electroceutical material is dry, it functions as an ordinary fabric. But if it gets dampenedsay, with saliva, vapour from a coughed updropletsor other bodily fluidsions in the liquid trigger an electrochemical reaction. The silver and zinc then generate a weak electric field that zaps pathogens on the surface.

The researchers co-developed the material with the biotechnology company Vomaris Innovations in 2012. Last year, they showed that the technology could be used to treat bacterial biofilms in wounds. A clinical trial is underway to further evaluate the fabrics effectiveness as a Food and Drug Administrationcleared dressing for wound care, Sen says.

In response to the Covid-19 pandemic, Sens team tested its existing material on a different coronavirus strain that causes a respiratory illness in pigs and on an unrelated type of pathogen called a lentivirus. We wanted to know how broadly this principle could be applicable, he says. In a study posted on the preprint server ChemRxiv in May, Sens team reported that its electroceutical fabric destabilised both viruses, leaving them unable to infect cells. The researchers plan to submit the results to a peer-reviewed journal as well.

To study the fabrics action, they placed a liquid solution containing viral particles onto the electroceutical fabric and a polyester control fabric without the metal dots. After the droplets were fully absorbed, and the samples had rested for one to five minutes, the researchers recovered viral particles from both fabrics and tested whether they could still infect the types of cells they typically target.

The data presented here show that, of the total virus that was recovered, a significant percentage was inactivated, says Jeff Karp, a professor of medicine at Brigham and Womens Hospital in Boston and co-leader of an N95 respirator working group at the Massachusetts General Brigham Center for COVIDInnovation. Karp, who was not involved with the study, adds that the researchers did not test all of the virus that they had placed on the cloth. In fact, the majority of virus was not recovered from the textiles examined in this study, he says. Sen responds that his team focused on sampling only enough viral particles to show that the fabric had rendered them unable to infect cells. The researchers recovered roughly 44 percent of the particles from the electroceutical fabric samples that had rested for one minute. And they retrieved 24 percent of them from the samples that had rested for five minutes.

The materials virus-fighting abilities have not been tested specifically on SARS-CoV-2, the coronavirus that causes Covid-19. The researchers findings with the two viruses they studied, however, gave them hope that this could apply more widely, Sen says. He adds that large-scale manufacturing of the electroceutical fabric is already possible and that the costs of producing it are relatively low. The metal dots could be printed directly onto the front surfaces of masks, he suggests. Or an electroceutical fabric could be inserted between the front of a mask and the wearers face.

If a virus-stopping PPE material were widely available, it could limit the novel coronaviruss ability to spread. There is a huge unmet need to better understand modes of viral transfer that lead to virus transmission, Karp says. As we develop a better understanding of this, there is a huge immediate need to develop and quickly apply solutions that can reduce transmission.

Metal dots are not the only potential approach. Paul Leu, director of an advanced materials laboratory at the University of Pittsburgh, and his colleagues are developing a textile coating that repels bodily fluids, proteins and bacteria. It also repels one strain of adenovirus that causes respiratory illness and another that causes conjunctivitis, as reported in ACS Applied Materials & Interfaces in April. Leus team has also not tested the material with the novel coronavirus itself, however. The main thing with testing [the coating on] SARS-CoV-2 is the biosafety level you need to test it, because its very hazardous, he says. Still, his team plans to see how well textiles with this coating repel a different coronavirus.

Leu says the coating, which remains repellent even after ultrasonic washing and scraping with a razor blade, could make PPE safer for wearers to take off. It could also be used on hospital bed linens, drapes and waiting room chairs, the researchers note in the study. But Leu points out that the coating is intended for use with medical textiles that are already considered reusable. His team has not tested it on single-use masks or N95s, but he thinks it could potentially damage them. Still, he says, the coating could work well for cloth masks such as those now being worn by many among the general public.

By developing materials that kill or repel viruses, researchers hope to make masks and other protective gear safer to remove and more effective against all viruses. If the common person were to have PPE that wouldnt spread infection, Sen says, I think thats a big, big deal.

View original post here:
Electrified fabric could zap the coronavirus on masks, clothing - Deccan Herald

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Market Dynamics

Growth Drivers

Challenges

Market Trends

Companies Profiled

For more information about this report visit https://www.researchandmarkets.com/r/ufteqn

Read more from the original source:
Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire

Market Industry Reports (MIR) has published a new report titled Regenerative Medicine Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2030. According to the report, the global regenerative medicine market was estimated to be over US$ 13 billion in 2019. It is anticipated to grow at a CAGR of 23.2%from 2019 to 2030.

Some of the prominent players in the global regenerative medicine market include:

Novartis AG,Integra LifeSciences Corporation,Vericel Corporation,MiMedx, Stryker,Spark Therapeutics, Inc.,Osiris Therapeutics, Inc.,Kite Pharma,Organogenesis Inc. and MEDIPOST among others.

Click Here to Get Acess of Sample Pages @https://www.marketindustryreports.com/pdf/254

Scope of Report:

The significant growth of the market can be attributed to increasing prevalence of chronic as well as genetic disorders followed by increasing demand of medicines and therapies that can help cure and prevent these disorders. Moreover, increasing private and government investments for research & development of regenerative medicines are anticipated to boost the regenerative medicine market over the forecast period. To obtain better insights regarding the market scenario, prominent players are increasingly focusing on mergers, acquisitions or collaborations with smaller regenerative medicine companies. For instance, in Jan 2020, Amgen announced a strategic collaboration with BeiGene a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer. This strategic collaboration will enable Amgen to expand its oncology presence in China.

In recent years, prevalence and incidences of chronic infectious diseases as well as genetic disorders is increasing. For instance, according to American Cancer Society, in 2019, there were around 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States. Such high incidence rates are thus increasing the demand of medicines that can help to prevent or cure such diseases. Such factors are expected to play a pivotal role in fueling the growth of the market during the forecast period.

Segmentation:

Regenerative Medicine Market By Type:Cell-Based Immunotherapy & Cell Therapy Products,Tissue-Engineering Products andGene Therapy Products

Application:Musculoskeletal Disorders,Oncology,Ocular Disorders,Wound Care and Diabetes

To Avail Limited Offers Get Interesting Discount @https://www.marketindustryreports.com/discount/254

This Regenerative Medicine market report holds answers to some important questions like:

1. What is the size of occupied by the prominent leaders for the forecast period, 2020 2030? What will be the share and the growth rate of the Regenerative Medicine market during the forecast period?2. What are the future prospects for the Regenerative Medicine industry in the coming years?Which trends are likely to contribute to the development rate of the industry during the forecast period, 2020 2030?3. What are the future prospects of the Regenerative Medicine industry for the forecast period, 2020 to 2030?4. Which countries are expected to grow at the fastest rate?5. Which factors have attributed to an increased sale worldwide?6. What is the present status of competitive development?

Table of Content

1 Introduction of Regenerative Medicine Market1.1 Industry Overview1.2 Scope of the Report1.3 Assumptions

2 Executive Summary

3 Research Framework by Market Industry Reports3.1 Data Mining3.2 Data Validation3.3 Primary Interviews3.4 Data Sources List

4 Regenerative Medicine Market Overview4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Limitations4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Product TypeOverview of Regenerative Medicine Market

6 Regenerative Medicine Market, By ApplicationOverview of Regenerative Medicine Market

7 Regenerative Medicine Market, By End UserOverview of Regenerative Medicine Market

To Know More Information Buy this Full Report @https://www.marketindustryreports.com/checkout/254

About Us

Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

Contact Us

Email: [emailprotected]Phone: +1 347 767 5477 ( US ) + 91 8956 767 535 ( IN ) + 44 131 463 4161 ( UK )Website:https://www.marketindustryreports.com

Read more:
Regenerative Medicine Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2030 - Cole of...

Global Regenerative Medicine market covers a detailed analysis of the market appearances, segmentation, size and progress, market shares, provincial collapses, competitive background, tendencies and several growth strategies for this Regenerative Medicine market. Likewise, the market appearances section of this study describes and defines the complete overview of the Regenerative Medicine market. The global Regenerative Medicine market report extent segment offers the market revenues, covering both the momentous growth of the industry and anticipating the upcoming market revenue. In addition, global market separations break down into the key sub-areas which gives a better idea about the market size.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/52

Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. Some of the important aspects analysed in the report includes market share, production, key regions, revenue rate as well as key players. This Regenerative Medicine market report also provides the readers with detailed figures at which the Regenerative Medicine market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the keyword is expected to mount and major factors driving markets growth.

In addition, the report include deep dive analysis of the market, which is one of the most important features of the Regenerative Medicine market. Furthermore, the need for making an impact is likely to boost the demand for the experts which are working in the market. Moreover, an in depth analysis of the competitors is also done to have an estimate for the Regenerative Medicine market. Moreover, the report provides historical information with future forecast over the forecast period. Production, market share, revenue rate, key regions and major vendors are some of the vital aspects analysed in the report. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users. The study on global Regenerative Medicine market, offers profound understandings about the Regenerative Medicine market covering all the essential aspects of the market.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

Potential consumers, market values, and the future scope for the Regenerative Medicine market are explained thoroughly to the users in this report. The key players of Regenerative Medicine industry, their product portfolio, market share, industry profiles is studied in this report. Adaptation of new ideas and accepting the latest trends are some the reasons for any markets growth. The Global Regenerative Medicine market research report gives the deep understanding about the regions where the market is impactful. It also elaborates the big and small vendors working actively all over the globe.

Regenerative Medicine market report studies the current state of the market to analyse the future opportunities and risks. Regenerative Medicine market report provides a 360-degree global market state. Potential consumers, market values, and the future scope for the Regenerative Medicine market are explained thoroughly to the users in this report.

For Any Query on the Regenerative Medicine Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original:
Regenerative Medicine Market 2020, by Brands, Prices, Sales, Distribution Channels, Production, Demand and Investment Opportunities to 2025 - Cole of...

Our company has built a platform to produce high-quality cells and tissues for regenerative medicine. That pursuit involves multiple disciplines, which means everyone here is an expert in a different language. Some of us are fluent in stem-cell biology, others in optical engineering, others in machine learning. When we started the company it wasnt possible to do biology and engineering under the same roof. When we finally moved into a shared space we were able to learn each others lexicons, and we became more strongly aligned. And now that were all working separately, the bonds created in that process have helped us deal with things. We cant discuss technical details at our desks anymore, but weve learned new ways of working together. Its important to stay in sync as a team, and in a covid-19 world thats never felt more true.

TIM O'CONNELL

Founded Blendoor, a job-search platform that hides candidates names and photos in the initial stages to reduce unconscious bias.

I started coding at 13, and that has gotten me pretty far in my career (Stanford, MIT, Microsoft). I once viewed humanities and social science education as nice-to-haves but not need-to-haves. It wasnt until I came face to face with the harsh realities of inequity and the paradox of meritocracy that I realized that artificial intelligence is far from solving many of our most challenging problems as a human race (for example, xenophobia, sexism, racism, homophobia, impostor syndrome, and unconscious bias).

The externalities that influence creativity, adoption, and scale are often more important than the innovation itself. To be a successful innovator one has to be really in tune with whats happening in the world on a global scale (or be really lucky, or better yet both). Venture capital has shortened the learning curve for some innovators, but bias has limited access to venture capital for many. Unconscious bias is like an odorless gasits imperceptible to most, but pervasive and deadly.

To optimize the innovation ecosystem, institutions must invest more in leveling the playing field. Today and for much of the documented past, innovation has been reserved for the children of middle- and upper-class parents. (Research the founders of companies valued at over $1 billion.) We laud the proverb Necessity is the mother of invention, but the people who grow up needing the most, independent of their intelligence, are often left out of the innovation game. As with all games, the best players emerge when the barriers to entry are low, the rules/standards are equally enforced, and there is high transparency across the board.

Audre Lorde once wrote: The masters tools will never dismantle the masters house.

I am a short, melanin-enriched, queer female on planet Earth. In some ways its easier to be innovative when youre invisible, but at some point, you need tools to scale: capital, team, mentorship. The one thing I know now that I wish I had known earlier is that my path toward getting the tools I need looks a lot different from the paths of others. Its not better nor worsesimply different. The hardest part is carving it out. Now that I know my path isnt blockedrather, it just didnt existIm way better equipped to win.

COURTESY PHOTO

Founded DotLab, which makes diagnostic tests focused on womens health.

About a decade ago I worked at the White House Office of Science and Technology Policy, whose goal was to speed up the commercialization of technologies being developed in federally funded labs. While there I saw that some of the most important work done by the government involved things the media paid no attention tofor example, the way it could use investments in research and development to fuel private--sector innovation.

In 2009, the Obama administration released the Strategy for American Innovation. The idea behind it was to establish the critical nature of federal government support for R&D. In particular it stressed the spillover effects, or the idea that investments in such research end up being beneficial to people unrelated to the original investment. Or to put it another way, R&D investment is a public good. Analyses at the time suggested that in order to produce economic growth we should be doubling or quadrupling our R&D investments. Instead that spending has since been slashed, especially in basic research.

President Obama also launched a Lab to Market Initiative meant to speed the path to market for technologies stemming from government--funded research. There were also pilot programs designed to increase the use of government-funded R&D facilities by entrepreneurs, create incentives to commercialization, and improve, among other things, the impact of the Small Business Innovation Research (SBIR) program.

My own company, DotLab, ended up being a beneficiary. We develop novel molecular diagnostic tests for prevalent yet underserved diseases affecting womens health. Its notoriously difficult for this field of early--stage diagnostics to attract private investment, because of unclear regulatory pathways, low reimbursement rates, or resistance to change among physiciansor all of the above. Many promising diagnostic technologies never make it to patients because its so hard for these types of companies to get financing. A grant from the SBIR was critical to our early success. I cant be sure that wed be here today without it.

COURTESY PHOTO

Founded Ubiquitous Energy, which makes transparent solar cells that can be put on windows or device screens.

I used to imagine innovators as individuals, as most people probably dothe genius inventor divining solutions in a lab or garage. But this picture that people have is not only wrong; it hinders our ability to innovate effectively.

Eight years ago I cofounded Ubiquitous Energy, a company based on an innovation Id helped to launch from an MIT laba transparent solar cell that promised new ways of deploying solar technology, like windows that generate energy or consumer devices powered by their own displays. I learned that in the messy, scrappy world of tech startups, the key to innovation is to make it a team sport.

Taking any innovation from the lab to commercial reality requires engaging with all sorts of people. You need to work with engineering, R&D, business development, and sales teams, as well as investors, advisors, and customers. By thoughtfully designing teams and carefully tending to the connections among them, you ensure that innovation doesnt happen in a vacuum. If you isolate the engineering team you risk creating an innovative technology that doesnt have a customer. If you listen only to the customer you might conceive of a product that cant practically be made. Neglect investors and you can find yourself with a business plan that nobody wants to fund.

Working among people with competing priorities takes more effort. It means encouraging communication so theyre aware of each others needs as they generate new ideas. You have to find a way to invite these ideas in, make it okay for people to disagree respectfully, and encourage the flow of ideas among the various groups. You need each person to focus on his or her task, but not so much that it creates boundaries and kills any sense of creativity in the group.

Ive found that viewing innovation as a team sport instills a creative culture that makes an organization better. The innovations that result are far greater than anything that might have come from any one person operating independently.

CHRIS SCIACCA / IBM RESEARCH

Founded Somalias first incubator and start-up accelerator; now at IBM Research.

People tend to think innovation can be neatly placed into two categories: incremental or disruptive. They also assume that the only category that really matters is the disruptive kind, where you dramatically transform markets or introduce a novel product. And yes, disruptive innovations in CRISPR, quantum computing, or batteries are undoubtedly worth the headlines.

But Ive learned that there is immense value in incremental innovation. When you improve an existing product to cut costs, or when you make that product more efficient or user friendly, thats what pays the bills. And in fact those little innovations can give you the needed tailwind to go after the disruptive ideas, which can take years to incubate and bring to fruition. Never underestimate the importance of incremental improvements.

TIM O'CONNELL

Cofounded Imprint Energy, which is developing thin, flexible, and safe print- able batteries.

As a CEO of a startup, you get used to hearing no. You also face an endless succession of what feel like earth--shattering crises, like nearly running out of cash, losing a key customer, discovering a widespread product failureor having to shut down operations because of a global pandemic. But it turns out that these disasters can actually be good for you. In fact, Im not sure you can innovate without them. Heres what all our crises have taught me.

Its good to be uncomfortable. We once had a key customer request a battery capability that wed never deployed before. The customer made it clear that if we couldnt develop this capability theyd be less confident in our product. We wrestled with the risks, not least of which was the potential embarrassment if we couldnt meet the customers needs. We knew wed face many technical problems with no obvious solutions if we tried to pull it off. Yet we decided to try to satisfy the customer, even if it wasnt obvious at first how we could get it done. A few weeks later we delivered something beyond what the customer had asked for, and weve since grown this capability into a powerful sales tool and potential revenue streamnot to mention it strengthened our relationship with the customer.

Short-term failure is good. A few years ago our company began to scale up our manufacturing output in response to a customers need. In the process we discovered aberrations we hadnt seen during smaller-scale production. Our team dived into failure analysis, and we finally attributed the problem to a single material within the battery. Wed used this material for years, but now we needed a replacement. Once we deployed that change, the battery quality, reliability, and manufacturability drastically improved.

Its okay to be vulnerable. One of my hardest days as Imprints CEO was the day I found out I was pregnant. We were in the middle of raising a funding round, we had begun scaling our manufacturing output, and I had been traveling nonstop for a year. Until that day, I had assumed that my role as CEO was to exude strength and confidence. With the mounting pressure I was harder on myself than I needed to be, and now I had the added stress of being pregnant. I decided to acknowledge to my team that I was overwhelmed. They rallied together and found ways to operate more efficiently and communicate more effectively, supporting me to focus my time and leverage on our most pressing goals. This gave me not only the space to plan for the companys future, but also the resiliency to prepare for my own new normal: leading while becoming a first-time mother.

Read the original:
Six tales from the trenches of running a startup - MIT Technology Review

DetailsCategory: Proteins and PeptidesPublished on Thursday, 18 June 2020 09:51Hits: 128

June 17, 2020 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; JCR) announced today that the results of the phase 1 and 2/3 clinical trials of Agalsidase Beta BS I.V. Infusion [JCR] (JR-051), recombinant Agalsidase Beta, for Fabry disease have been published in the electronic edition of Molecular Genetics and Metabolism, the official journal of Society for Inherited Metabolic Disorders. This is JCRs first product for enzyme replacement therapy (ERT) for Lysosomal Storage Disorders (LSDs), also the first of the kind manufactured in Japan. Agalsidase Beta BS I.V. Infusion [JCR] has been launched since November 2018 as the first biosimilar for the treatment of rare diseases. A summary of the article is as follows.

Title: Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies

Digital Object Identifier: https://doi.org/10.1016/j.ymgme.2020.04.003

Summary The Phase 1 and 2/3 studies were conducted with the aim to verify clinical comparability of JR051 and an upfront biopharmaceutical (agalsidase beta). The results demonstrated that JR051 and agalsidase beta are comparable in terms of efficacy and safety.

Phase 1 study: 20 healthy adult male volunteers were administered JR-051 and agalsidase beta to confirm pharmacokinetic equivalence in a randomized, double-blind, parallel-group manner. The study demonstrated comparable pharmacokinetic profiles of JR-051 and agalsidase beta.

Phase 2/3 study: 16 patients with Fabry disease underwent treatment with agalsidase beta (1mg/kg, once every other week), then were switched to intravenous administrations of JR-051 (1 mg/kg, once every other week).

Efficacy: The 95% confidence intervals of the ratios of the GL-3 plasma concentrations (primary endpoint) during the agalsidase beta treatment, as well as those of Lyso-GL-3, to the respective plasma concentrations after 26 and 52 week-administrations of JR-051 were within pre-determined equivalence acceptability ranges.

Safety: No severe infusion associated reactions (IARs), such as anaphylactic shock, were observed. One IAR, commonly observed with the ERT for Fabry disease, was reported in a patient after JR-051 administration.

[About JCR Pharmaceuticals]

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, Contributing towards peoples healthcare through pharmaceutical products drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

SOURCE: JCR Pharmaceuticals

Go here to see the original:
Agalsidase Beta BS IV Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in...

Borja de la Sen-Corcuera,1,2 Jess Montero-Iruzubieta,3,4 Ronald M Snchez-vila,1,5 Gorka Orive,1,2 Eduardo Anitua,1,2 Manuel Caro-Magdaleno,4 Jess Merayo-Lloves5

1Biotechnology Institute (BTI), Vitoria, Spain; 2University Institute for Regenerative Medicine and Oral Implantology (UIRMI), Vitoria, Spain; 3Clnica Cartujavisin, Sevilla, Spain; 4Hospital Universitario Virgen de Macarena, Sevilla, Spain; 5Instituto Universitario Fernndez-Vega, Fundacin de Investigacin Oftalmolgica, Universidad de Oviedo, Oviedo, Spain

Correspondence: Ronald M Snchez-vilaInstituto Universitario Fernndez-Vega, Fundacin de Investigacin Oftalmolgica, Avda Dres Fernndez-Vega Num 34, Oviedo E-33012 Principado de Asturias, SpainTel +34 985240141Fax +34 985233288Email ronald.sanchezavila@gmail.com

Purpose: The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy.Patients and Methods: This is a retrospective study that included patients diagnosed with CC, in whom isPRGF was used in different phases (I: eye drops; II: eye drops and injectable; III: eye drops, injectable and surgical treatment) to achieve control of the inflammation. As a clinical follow-up of the patients, the better corrected visual acuity (BCVA), degree of inflammation (measured from 1 to 4), the severity of the CC, Schirmer I test, IOP and TBUT were analyzed. The adverse events were also evaluated.Results: Ten eyes (6 patients) were evaluated, 50% corresponded to StevensJohnson Syndrome and 50% to ocular mucous membrane pemphigoid. The mean age was 59.7 16.5 (39 80) years, and 50% were women. Fifty per cent of the cases were initially considered severe CC, and 10% of the cases (one eye of one patient) were considered severe CC at the end of the treatment (p = 0.046). The initial degree of inflammation was 2 in 4 eyes, 3 in two eyes, and 4 in 4 eyes, and final inflammation degree was 1 in all cases (p = 0.004). Twenty per cent of the cases achieved stability in Phase I of the treatment with immunosafe PRGF, 70% with both Phases I and II, and only one case underwent Phase III to achieve stability. The IOP improved significantly (p = 0.027) though the BCVA, TBUT and Schirmer I test showed no significant changes. The follow-up time was 23.1 6.7 (13.6 30.3) months. No adverse effects were reported.Conclusion: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.

Keywords: immunosafe plasma rich in growth factors, isPRGF, StevensJohnson syndrome, ocular mucous membrane pemphigoid, blood derivatives

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More here:
Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunc | OPTH - Dove Medical Press

Post COVID-19 Impact on 3D Cell Culture Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following: Long-term and short-term impact of Covid-19 on the market Cascading impact of Covid-19 on 3D Cell Culture Market, due to the impact on its extended ecosystem Understanding the market behavior Pre- and Post-COVID-19 pandemic Strategy suggestions to overcome the negative impact or turn the positive impact into an opportunity Well help you fight this crisis through our business intelligence solutions.

Connect with Analyst to Reveal How COVID-19 Impacting On 3D Cell Culture Market: https://www.researchdive.com/connect-to-analyst/73

Pre COVID-19 Analysis of 3D Cell Culture Market

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patients own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture organs-on-chips. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Download Exclusive Sample Copy of the Report at: https://www.researchdive.com/download-sample/73

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

View out Trending Reports with the Impact of COVID-19: https://www.researchdive.com/covid-19-insights

The major 3D Cell Culture manufacturers include QGel SA, Hrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Link:
What Is the Impact of COVID-19 on 3D Cell Culture Market During Projected Period of 2020-2026? - Cole of Duty

NEW YORK, June 17, 2020 /PRNewswire/ -- The globalNanocellulose marketis forecast to reach USD 1.08 Billion by 2027, according to a new report by Reports and Data. The market is seeing an expanded interest from the composites sector owing to its critical characteristics, including biodegradability, non-toxicity, and sustainability, along with thixotropic Nanocellulose properties. However, volatile prices of raw materials arising necessity for exploring and adopting other content as a substitute to reduce the overall cost of the operation will be hampering the demand for the market.

Cosmetics would have substantial potential for Nanocellulose across the forecast period. It is used as a synthetic covering agent for fingers, eyes, eyebrows, or eyelashes in cosmetics. The product also provides antioxidant properties and is now used in products for sun care. It is also used for wound dressings in the surgical profession and regenerative medicine. Other uses include pharmaceuticals, tobacco filter additives, computer components, electronic displays, condensers, lithium battery films, lightweight body armor, loudspeaker membranes, and ballistic glass. However, low awareness about product use and high prices may, in the coming years, somehow hamper the demand. Nano fibrillated cellulose held the highest share in the overall market in 2019.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3207

They possess exceptional properties, including superior strength, lightweight, transparency, and rigidity, among others, which makes them viable for many commercial applications across composites, oil & gas, food & beverage, automotive, aerospace, and personal care industries. Nano-fibrillated cellulose could also be a future replacement for plastic films in composite packaging due to the low oxygen permeability. The composites segment was the largest application segment in the overall market in 2019 by volume. Nowadays, composites are used widely in many applications. It is used in refurbishments as filler stuff. End-users are increasingly concerned about the application of synthetic fillers in composites and the environmental concerns associated with that application. Thus, replacing synthetic pads with natural ones like cellulose fibers will bring many positive environmental benefits as the product offers good thermal conductivity, low density, and biodegradability, owing to increasing personal care and food & beverage industries in the area. The market in the Asia Pacific region will propel the product demand over the projected period. Countries, including China, Japan, and India, have played a significant role in enhancing the nanotech profile of the region. Japan's AIST Nanocellulose Forum, for example, is focused on strengthening cooperation between industry, universities, and government.

The COVID-19 Impact:

As the COVID-19 crisis continues to intensify, producers are quickly adapting their activity and purchasing objectives to satisfy the demands of a pandemic that has limited the need for Nanocellulose in the market. A sequence of both positive and negative shocks may arise over a few months, as producers and their vendors respond to the evolving demands of customers. The export-dependent economies in several nations look weak, with an adverse global circumstance. Global Nanocellulose markets are reshaped by the effects of this pandemic, as some suppliers are either shutting down or reducing their output, due to a lack of demand from the downstream market. Although others are getting their production suspended as a precautionary step by their respective governments to prevent the spread of the virus. In certain countries, consumers based on being more regional by looking at the magnitude of the epidemic and the consequent behavior of the national authorities themselves. Under these circumstances, market conditions of the Asia Pacific regions were quite dynamic, weakening regularly, making stabilizing themselves difficult.

To identify the key trends in the industry, click on the link below:https://www.reportsanddata.com/report-detail/nanocellulose-market

Further key findings from the report suggest

Order Now: https://www.reportsanddata.com/checkout-form/3207

For the purpose of this report, Reports and Data have segmented into the global Nanocellulose market on the basis of product, distribution channel, application, and region:

Product Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Distribution Channel Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Application Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Regional Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Browse more similar reports on Materials and Chemicalscategory by Reports And Data

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John WHead of Business DevelopmentReports And Data | Web: http://www.reportsanddata.com Direct Line: +1-212-710-1370E-mail: [emailprotected] LinkedIn | Twitter | Blogs

SOURCE Reports And Data

Continued here:
Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire

Post COVID-19 Impact on 3D Cell Culture Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following: Long-term and short-term impact of Covid-19 on the market Cascading impact of Covid-19 on 3D Cell Culture Market, due to the impact on its extended ecosystem Understanding the market behavior Pre- and Post-COVID-19 pandemic Strategy suggestions to overcome the negative impact or turn the positive impact into an opportunity Well help you fight this crisis through our business intelligence solutions.

Connect with Analyst to Reveal How COVID-19 Impacting On 3D Cell Culture Market: https://www.researchdive.com/connect-to-analyst/73

Pre COVID-19 Analysis of 3D Cell Culture Market

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patients own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture organs-on-chips. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Download Exclusive Sample Copy of the Report at: https://www.researchdive.com/download-sample/73

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

View out Trending Reports with the Impact of COVID-19: https://www.researchdive.com/covid-19-insights

The major 3D Cell Culture manufacturers include QGel SA, Hrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Go here to see the original:
What are the 3D Cell Culture Market Key Insights and COVID-19 Business Impact? - 3rd Watch News

Biopreservation Market will exceed USD 9.5 billion by 2024; as per a new research report.

Increasing investment in R&D activities worldwide will drive the biopreservation market growth over the forecast period. Companies and research organizations are taking efforts to develop efficient and effective product and services for biopreservation. Increasing usage of biological laboratory specimens in various research and clinical trials should further boost the biopreservation business growth.

Growing prevalence of lifestyle disorders in developed as well as developing countries will positively impact the industry growth over the coming years. Rising incidence of organ deformities coupled with shortage of organ donors for transplantation will increase the demand for regenerative medicine. Need for appropriate storage and preservation of the biological preparations will surge the demand for biopreservation equipment thereby augmenting industry growth. However, stringent regulations pertaining to manufacturing biopreservation equipment and complications associated with required temperature maintenance may hamper the business growth during the forecast period.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/762

Media segment accounted for USD 0.5 billion in 2017 and is estimated to show significant growth over forecast period. The segment growth is accredited to increasing usage of media in biopreservation process to improve post-thaw cell viability, yield and recovery. Growing demand for biopreservation media such as pre-formulated and home-brew media should further increase segment size over the coming years.

Drug discovery segment will experience 13.5% CAGR by 2024 and segmental growth will be attributable to increasing investment in R&D activities to develop efficient treatment for chronic disease. Growing adoption of stem cell models and human tissues as experimental models for preclinical drug development will foster the demand for proper preservation and storage of these biologics thereby accelerating business growth.

CD34+ segment accounted for 16.0% revenue share in 2017 due to its wide application in research and its ability to differentiate into various cell types. CD34+ cells from umbilical cord blood (UCB) can be used in treatment of chronic and non-healing wounds in patients with type 2 diabetes mellitus. Such benefits should augment the segmental revenue size during the forecast period.

Get In-depth table of contents @ https://www.gminsights.com/toc/detail/biopreservation-market

U.S. biopreservation market accounted for USD 1.6 billion in 2017 and will show similar trend during the forecast timeline. Technological developments in the U.S. coupled with rising adoption of regenerative medicine in disease treatment will surge the demand for biopreservation products. Moreover, high healthcare expenditure and advancement in healthcare facilities will further drive the business growth.

Some of the notable competitors operating in biopreservation market include: BioCision, Biomatrica, Chart MVE Biomedical, BioLife Solutions, LabVantage Solutions, Custom Biogenic Systems Atlanta Biologics, Taylor-Wharton Cryogenics, Thermo Fisher Scientific, Panasonic Biomedical, Qiagen, and VWR International. Industry players are majorly focusing on inorganic strategies such as partnership, merger, acquisition and novel product launch to strengthen their existing product portfolio and maintain market position.

See the rest here:
Biopreservation Market share research by applications and regions for 2018 2024 - Cole of Duty

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.Use-type InsightsThe clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.TherapyType Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the article here:
Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Cole of Duty

Published 18 June 2020

An online community consultation has been launched today with the intention of developing a new mixed-use neighbourhood, as part of plans by Edinburgh BioQuarter to create a new Health Innovation District.

A new fly-through of the proposed development shows the latest design phase of the masterplan to the local community, with the consultation seeking feedback on how the site will evolve over the next decade and beyond.

BioQuarter, which sits to the south east of the city, is already home to the Royal Infirmary of Edinburgh, the University of Edinburgh Medical School and Centre for Regenerative Medicine, alongside a number of medical research institutes and life sciences businesses. The ambition is that BioQuarter will grow to a community of more than 20,000 people who will live, work or study at the 167-acre site. The expansion will support an estimated 9,000 longer term new jobs, plus additional construction jobs, while greatly expanding the numbers of spin out and start-up companies.

BioQuarters Partners the City of Edinburgh Council, NHS Lothian, Scottish Enterprise, and the University of Edinburgh are updating their existing masterplan to include a wider mix of uses including an increase in residential and commercial properties planned at the site. The consultation on the plan will run online due to current restrictions caused by COVID-19 between June 18 and July 13.

Proposals featured as part of the online consultation include the construction of shops, cafs, a gym, hotel, nursery and residential homes set alongside state-of-the-art innovation, teaching and healthcare facilities.

With the commitment of its partners, BioQuarter has already benefitted from over 500 million of public capital investment and has a further 300m of investment planned over the next five years. The site is also home to innovative research including STOPCOVID, a project aiming to test existing and experimental drugs as treatments for COVID-19, spearheaded by the University of Edinburghs Centre for Inflammation Research.

Commenting on the launch of the consultation, Anna Stamp, Edinburgh BioQuarter, interim programme director, said: Over the past two decades BioQuarter has grown as a place for health innovation with some of the countrys top medical research and life sciences businesses working together across the site.

We want your views to help shape BioQuarters development. This is an exciting time as we look to create a new community in the city; a vibrant neighbourhood that promotes health and wellbeing and complements its surrounding areas.

We have a unique opportunity here, which, if developed in the right way, can deliver huge benefits to the city, including economic growth, jobs skills and education. As part of the development of our Health Innovation District, we want to make sure it includes the right mix of amenities that will ensure it becomes a great new place to live, work and discover.

Council leader Adam McVey said: Im delighted to see plans progressing for this hugely exciting project for Edinburgh. Id encourage everyone to feed into the consultation for this cutting-edge development. Life sciences have long been extremely valuable as a sector here in Edinburgh, and the BioQuarter will play a crucial role in its ongoing success. This can make a massive contribution to the ongoing regeneration of the south east of the city.

This scheme will create a whole new community of people, with access to a vibrant new public square. In addition to this, its estimated the development will create around 9,000 new local jobs, with many more construction roles being created while it is being built.

Details on the development can be found here.

See the rest here:
Edinburgh BioQuarter consults on Health Innovation District - Scottish Housing News

When Dr Yendry Ventura began work to set up the Abu Dhabi Stem Cell Centre in late 2018, there was, he says, nothing else "related to stem cell therapy in the emirate.

Fast forward to today and the situation has changed dramatically. After opening in December last year, the centre has already received international press coverage over to its research into a treatment for Covid-19.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

What characterises the method, says Dr Ventura, is that very little manipulation of the cells is needed for the treatment to be effective.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

Dr Yendry Ventura

We separate a specific layer of cells from the blood, Dr Ventura told The National. Were the first one to use these cells with this route with this method.

We believe this way the cells can be aimed much better to the affected organs - the upper and lower respiratory tract.

In April, the centres efforts to develop a Covid-19 treatment led to the recovery of all 73 patients the treatment was initially trialled on. A quarter had been in intensive care.

The results appeared so promising that this month the centre secured intellectual property rights to the technique, allowing the treatment to be widely licensed, including to facilities abroad.

The ongoing work exemplifies how the centres specialists have been able to apply their expertise to help in a time of crisis, Dr Ventura said.

But the new research is a departure from the facilitys usual purpose, which involves developing cutting-edge stem cell treatments for conditions such as cancer and heart disease.

Stem cells were first extracted from humans and grown in laboratories less than a quarter of a century ago.

The human body is mostly made of specialised cell types, such as heart muscle cells, kidney cells or nerve cells, all of which have a particular form related to their function.

Stem cells, however, have not yet undergone the process of developing into a specialised cell type, and are able to be manipulated to perform a specific function.

In adults, stem cells are found in tissues including fat and bone marrow, and these can be turned into cell types.

One technique that the Abu Dhabi Stem Cell Centre plans to implement is haematopoietic stem cell transplantation, which involves stem cells being removed from an individual who is due to have cancer treatment.

The cells are then processed in a laboratory and injected into the patient after they have undergone chemotherapy or radiotherapy.

In this way, they can replace stem cells destroyed by the treatment, allowing a patient to tolerate a higher dose of therapy.

Dr Ventura says that similar treatments were applicable to most cancers of the blood as well as cancers that produce solid tumours.

There are many of these therapies still in research stage, but if you conquer this research, you can have a programme in which you can ... treat many kinds of cancers at the same time in one centre, he said.

The reality is that cell therapy is curing cancer We need to improve this therapy and make it available for many other people.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

You can create in the future, if you have the right technologies, even artificial organs.

Set up with private sector funding in collaboration with the UAE authorities, the Abu Dhabi Stem Cell Centre works closely with experts at Sheikh Khalifa Medical City.

But the institution is keen to forge further partnerships with both public and private sector medical institutions.

Currently, it operates seven days a week and has more than 100 staff, including nurses, technicians and doctors who specialise in immunology, haematology, pathology, orthopaedics, urology and radiology.

In another initiative, the facility has recently begun running Minimal Residual Disease tests, which look at how many malignant cells remain in a patients blood or bone marrow.

These tests are useful for people with a variety of blood cancers, including lymphoma, leukaemia and myeloma. But they require fresh samples from the patient, so the lack of UAE testing facilities has, until now, required patients to travel abroad.

We try to implement the tests here in the Abu Dhabi Stem Cell Centre so that the patient does not need to travel anymore, said Dr Ventura.

Updated: June 17, 2020 04:31 PM

Read more here:
Coronavirus: inside the UAE stem cell centre working to treat Covid-19 - The National

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Key benefits

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking

2.1. Introduction

2.2. Regenerative Medicine partnering over the years

2.3. Most active Regenerative Medicine dealmakers

2.4. Regenerative Medicine partnering by deal type

2.5. Regenerative Medicine partnering by therapy area

2.6. Deal terms for Regenerative Medicine partnering

2.6.1 Regenerative Medicine partnering headline values

2.6.2 Regenerative Medicine deal upfront payments7

2.6.3 Regenerative Medicine deal milestone payments

2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals

3.1. Introduction

3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers

4.1. Introduction

4.2. Most active Regenerative Medicine dealmakers

4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory

5.1. Introduction

5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/damlsx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

See the rest here:
Insights on Global Regenerative Medicine Partnering Terms and Agreements (2014 to 2020) - ResearchAndMarkets.com - Business Wire

Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005336/en/

Technavio has announced its latest market research report titled Global Regenerative Medicine Market 2020-2024 (Graphic: Business Wire)

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Request for Technavio's latest reports on directly and indirectly impacted markets. Market estimates include pre- and post-COVID-19 impact on the Regenerative Medicine Market Download free sample report

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. The increasing prevalence of chronic diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The increasing prevalence of chronic diseases has been instrumental in driving the growth of the market. However, uncertainties in regulatory approval might hamper market growth.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. https://www.technavio.com/report/regenerative-medicine-market-industry-analysis

Regenerative Medicine Market 2020-2024: Segmentation

Regenerative Medicine Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171

Regenerative Medicine Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our regenerative medicine market report covers the following areas:

This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Regenerative Medicine Market 2020-2024: Key Highlights

Table of Contents:

Story continues

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005336/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

See original here:
COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio...